Arbutus Biopharma (ABUS) Misses Q4 EPS by 33c

Arbutus Biopharma (NASDAQ: ABUS) reported Q4 EPS of ($0.46), $0.33 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $39 million versus the consensus estimate of $6.18 million.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
• S&P 500 may pull back before midterms, but Citi says buy the dip
• Is the global equity rally broadening? UBS weighs in